Budésonide (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Budésonide" in French language version.

refsWebsite

Global rank French rank

4nih.gov

4^th place

12^th place

2issn.org

57^th place

4^th place

2doi.org

2^nd place

3^rd place

2reuters.com

49^th place

87^th place

1qmul.ac.uk

1,735^th place

168^th place

1biam2.org

low place

7,317^th place

1genengnews.com

low place

1fda.gov

447^th place

1,409^th place

1pharmgkb.org

low place

1emedicinehealth.com

8,799^th place

low place

1mhra.gov.uk

low place

1hhs.gov

5,973^rd place

low place

1drugs.com

399^th place

2,761^st place

1principletrial.org

low place

1bmj.com

1,226^th place

347^th place

1ox.ac.uk

613^th place

961^st place

1medrxiv.org

low place

1thelancet.com

2,393^rd place

506^th place

1mohfw.gov.in

low place

1who.int

195^th place

221^st place

biam2.org

Propriétés du budésonide

bmj.com

Covid-19: Budesonide shortens recovery time in patients not admitted to hospital, study finds

doi.org

dx.doi.org

Stefanos Bonovas, Georgios K. Nikolopoulos, Daniele Piovani et Marien González-Lorenzo, « Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis », British Journal of Clinical Pharmacology, vol. 85, n^o 10,‎ octobre 2019, p. 2244–2254 (ISSN 1365-2125, PMID 31269287, PMCID 6783624, DOI 10.1111/bcp.14051, lire en ligne, consulté le 24 décembre 2022)
Jonathan Barratt, Richard Lafayette, Jens Kristensen et Andrew Stone, « Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy », Kidney International,‎ 19 octobre 2022, S0085–2538(22)00836–5 (ISSN 1523-1755, PMID 36270561, DOI 10.1016/j.kint.2022.09.017, lire en ligne, consulté le 24 décembre 2022)

drugs.com

(en) https://www.drugs.com/rhinocort.html

emedicinehealth.com

(en) BUDESONIDE - NASAL AEROSOL INHALER (Rhinocort) side effects, medical uses, and drug interactions

fda.gov

(en) Center for Drug Evaluation and Research, « FDA approves first drug to decrease urine protein in IgA nephropathy, a rare kidney disease », FDA,‎ 17 décembre 2021 (lire en ligne, consulté le 24 décembre 2022)

genengnews.com

(en) http://www.genengnews.com/gen-news-highlights/positive-phase-iii-data-mean-cosmo-and-santarus-plan-2011-nda-for-ulcerative-colitis-drug/81244010/

hhs.gov

oig.hhs.gov

(en) http://www.oig.hhs.gov/publications/docs/workplan/2010/Work_Plan_FY_2010.pdf Office of the Inspector General. p 26.

issn.org

portal.issn.org

Stefanos Bonovas, Georgios K. Nikolopoulos, Daniele Piovani et Marien González-Lorenzo, « Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis », British Journal of Clinical Pharmacology, vol. 85, n^o 10,‎ octobre 2019, p. 2244–2254 (ISSN 1365-2125, PMID 31269287, PMCID 6783624, DOI 10.1111/bcp.14051, lire en ligne, consulté le 24 décembre 2022)
Jonathan Barratt, Richard Lafayette, Jens Kristensen et Andrew Stone, « Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy », Kidney International,‎ 19 octobre 2022, S0085–2538(22)00836–5 (ISSN 1523-1755, PMID 36270561, DOI 10.1016/j.kint.2022.09.017, lire en ligne, consulté le 24 décembre 2022)

medrxiv.org

(en) Sanjay Ramakrishnan et al., Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial, medrxiv.org, 9 février 2021, doi.org/10.1101/2021.02.04.21251134

mhra.gov.uk

(en) http://www.mhra.gov.uk/home/groups/is-md/documents/drugalert/con1002579.pdf Rappel d'AstraZeneca : Pulmicort

mohfw.gov.in

Clinical management protocol for Covid-19 (In adults)

nih.gov

ncbi.nlm.nih.gov

Stefanos Bonovas, Georgios K. Nikolopoulos, Daniele Piovani et Marien González-Lorenzo, « Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis », British Journal of Clinical Pharmacology, vol. 85, n^o 10,‎ octobre 2019, p. 2244–2254 (ISSN 1365-2125, PMID 31269287, PMCID 6783624, DOI 10.1111/bcp.14051, lire en ligne, consulté le 24 décembre 2022)
Jonathan Barratt, Richard Lafayette, Jens Kristensen et Andrew Stone, « Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy », Kidney International,‎ 19 octobre 2022, S0085–2538(22)00836–5 (ISSN 1523-1755, PMID 36270561, DOI 10.1016/j.kint.2022.09.017, lire en ligne, consulté le 24 décembre 2022)

pubmed.ncbi.nlm.nih.gov

Stefanos Bonovas, Georgios K. Nikolopoulos, Daniele Piovani et Marien González-Lorenzo, « Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis », British Journal of Clinical Pharmacology, vol. 85, n^o 10,‎ octobre 2019, p. 2244–2254 (ISSN 1365-2125, PMID 31269287, PMCID 6783624, DOI 10.1111/bcp.14051, lire en ligne, consulté le 24 décembre 2022)
Jonathan Barratt, Richard Lafayette, Jens Kristensen et Andrew Stone, « Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy », Kidney International,‎ 19 octobre 2022, S0085–2538(22)00836–5 (ISSN 1523-1755, PMID 36270561, DOI 10.1016/j.kint.2022.09.017, lire en ligne, consulté le 24 décembre 2022)